Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Stalevo

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
OBJECTIVE To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson… Expand
Review
2013
Review
2013
The results of the large-scale study STRIDE-PD of patients with Parkinson's disease (PD) are presented. The aim of the study was… Expand
2013
2013
The results of the large-scale study STRIDE-PD of patients with Parkinson's disease (PD) are presented. The aim of the study was… Expand
2011
2011
All patients with Parkinson's disease (PD) with motor fluctuations due to long-term levodopa therapy have at least one non-motor… Expand
2011
2011
All patients with Parkinson's disease (PD) with motor fluctuations due to long-term levodopa therapy have at least one non-motor… Expand
2009
2009
The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson… Expand
2009
2009
UNLABELLED The most effective symptomatic treatment for Parkinson's disease (PD) is levodopa/dopa decarboxylase (DDC)-inhibitor… Expand
2008
2008
The addition of entacapone to levodopa‐carbidopa (LC) or the switch from LC to a tablet containing levodopa–carbidopa–entacapone… Expand
2006
2006
Objectives and methods –  This study investigated the ease with which 52 Parkinson's disease patients already receiving adjunct… Expand
Highly Cited
2005
Highly Cited
2005
The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo® (levodopa, carbidopa and entacapone… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2